Baker Bros. Advisors LP Assembly Biosciences, Inc. Transaction History

Baker Bros. Advisors LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$3.14 - $3.9 $6.62 Million - $8.22 Million	-2,108,621 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$3.8 - $4.56 $2.16 Million - $2.59 Million	567,203 Added 36.8%	2,108,621 $8.18 Million
Q3 2020 Nov 16, 2020	SELL	$15.08 - $27.04 $3,016 - $5,408	-200 Reduced 0.01%	1,541,418 $25.3 Million
Q4 2019 Feb 14, 2020	BUY	$8.36 - $23.81 $6.17 Million - $17.6 Million	738,372 Added 91.92%	1,541,618 $31.5 Million
Q2 2019 Aug 14, 2019	BUY	$12.9 - $20.8 $8.45 Million - $13.6 Million	654,659 Added 440.59%	803,246 $10.8 Million
Q2 2018 Aug 14, 2018	SELL	$39.21 - $50.29 $1.77 Million - $2.27 Million	-45,200 Reduced 23.32%	148,587 $5.83 Million
Q1 2018 May 15, 2018	SELL	$41.7 - $64.16 $5.38 Million - $8.27 Million	-128,940 Reduced 39.95%	193,787 $9.52 Million
Q4 2017 Feb 14, 2018	BUY	$28.58 - $49.91 $2.08 Million - $3.63 Million	72,727 Added 29.09%	322,727 $14.6 Million
Q3 2017 Nov 14, 2017	BUY	$23.08 - $34.92 $5.77 Million - $8.73 Million	250,000	250,000 $8.73 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $822M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.